These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19136199)

  • 1. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.
    Naito S; Yamamoto N; Takayama T; Muramoto M; Shinohara N; Nishiyama K; Takahashi A; Maruyama R; Saika T; Hoshi S; Nagao K; Yamamoto S; Sugimura I; Uemura H; Koga S; Takahashi M; Ito F; Ozono S; Terachi T; Naito S; Tomita Y
    Eur Urol; 2010 Feb; 57(2):317-25. PubMed ID: 19136199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
    Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
    J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial comment on: prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients.
    Ohlmann CH
    Eur Urol; 2010 Feb; 57(2):325-6. PubMed ID: 19136198
    [No Abstract]   [Full Text] [Related]  

  • 4. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
    Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
    Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
    Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
    Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
    Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.
    Hofmann HS; Neef H; Krohe K; Andreev P; Silber RE
    Eur Urol; 2005 Jul; 48(1):77-81; discussion 81-2. PubMed ID: 15967255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone.
    Toyoda Y; Shinohara N; Harabayashi T; Abe T; Akino T; Sazawa A; Nonomura K
    Eur Urol; 2007 Jul; 52(1):163-8. PubMed ID: 17098353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma.
    Pflanz S; Brookman-Amissah S; Roigas J; Kendel F; Hoschke B; May M
    Scand J Urol Nephrol; 2008; 42(6):507-13. PubMed ID: 19031267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates?
    Denzinger S; Otto W; Burger M; Hammerschmied C; Junker K; Hartmann A; Wieland WF; Walter B
    World J Surg Oncol; 2007 Feb; 5():16. PubMed ID: 17280613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma.
    Jung EJ; Lee HJ; Kwak C; Ku JH; Moon KC
    Urology; 2009 Jan; 73(1):137-41. PubMed ID: 18950844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: implications for clinical trial design and interpretation.
    Patil S; Ishill N; Deluca J; Motzer RJ
    Cancer; 2010 Jan; 116(2):347-54. PubMed ID: 19921736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.